CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

02 May 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

27 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

19 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

18 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

12 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

05 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

09 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

23 Feb 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

21 Feb 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

07 Feb 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Leadership Team Update

06 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

02 Feb 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

22 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

10 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 06:15:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

09 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

08 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

02 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

04 Oct 2022 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

27 Sep 2022 06:05:00 By Nasdaq GlobeNewswire